...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrinology >Combined Treatment With GH and IGF-I: Additive Effect on Cortical Bone Mass But Not on Linear Bone Growth in Female Rats
【24h】

Combined Treatment With GH and IGF-I: Additive Effect on Cortical Bone Mass But Not on Linear Bone Growth in Female Rats

机译：GH和IGF-I的联合治疗：对雌性大鼠的骨皮质质量有累加作用，但对线性骨生长没有作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The growth-promoting effect of combined therapy with GH and IGF-I in normal rats is not known. We therefore investigated the efficacy of treatment with recombinant human (rh) GH and/or rhIGF-I on longitudinal bone growth and bone mass in intact, prepubertal, female Sprague-Dawley rats. rhGH was injected twice daily sc (5 mg/kg.d) and rhIGF-I continuously infused sc (2.2 or 4.4 mg/kg.d) for 28 days. Longitudinal bone growth was monitored by weekly x-rays of tibiae and nose-anus length measurements, and tibial growth plate histomorphology was analyzed. Bone mass was evaluated by peripheral quantitative computed tomography. In addition, serum levels of IGF-I, rat GH, acid labile subunit, IGF binding protein-3, 150-kDa ternary complex formation, and markers of bone formation and degradation were measured. Monotherapy with rhGH was more effective than rhIGF-I (4.4 mg/kg.d) to increase tibia and nose-anus length, whereas combined therapy did not further increase tibia, or nose-anus, lengths or growth plate height. In contrast, combined rhGH and rhIGF-I (4.4 mg/kg.d) therapy had an additive stimulatory effect on cortical bone mass vs rhGH alone. Combined treatment with rhGH and rhIGF-I resulted in markedly higher serum IGF-I concentrations vs rhGH alone but did not compromise the endogenous secretion of GH. We conclude that rhIGF-I treatment augments cortical bone mass but does not further improve bone growth in rhGH-treated young, intact, female rats.
机译：GH和IGF-I联合治疗对正常大鼠的促生长作用尚不清楚。因此，我们研究了用重组人（rh）GH和/或rhIGF-1治疗完整，青春期前雌性Sprague-Dawley大鼠纵向骨生长和骨量的功效。每天两次皮下注射rhGH（5 mg / kg.d），rhIGF-1连续皮下注射（2.2或4.4 mg / kg.d），持续28天。通过每周一次的胫骨X射线和鼻-肛门长度测量监测纵向骨生长，并分析胫骨生长板的组织形态。通过外周定量计算机断层摄影术评估骨质量。另外，测量了血清IGF-1，大鼠GH，酸不稳定亚基，IGF结合蛋白3、150kDa三元复合物的形成以及骨形成和降解的标志物。 rhGH的单一疗法比rhIGF-1（4.4 mg / kg.d）更有效地增加胫骨和鼻肛门的长度，而联合治疗并未进一步增加胫骨或鼻肛门的长度或生长板的高度。相比之下，与单独的rhGH相比，rhGH和rhIGF-I（4.4 mg / kg.d）的联合治疗对皮质骨量具有累加刺激作用。与单独的rhGH相比，rhGH和rhIGF-1的联合治疗可显着提高血清IGF-1的浓度，但不会损害GH的内源性分泌。我们得出的结论是，rhIGF-I治疗可增加皮质骨量，但不会进一步改善rhGH治疗的年轻完整雌性大鼠的骨生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号